Sarcopenia Market Report and Forecast 2024-2032

Sarcopenia Market Report and Forecast 2024-2032

Sarcopenia Market Report and Forecast 2024-2032

Sarcopenia Market Outlook

The sarcopenia market size is expected to grow at a CAGR of 4.3% during the forecast period of 2024-2032. The market is driven by the growing geriatric population and the increased research activities to mitigate the impact of sarcopenia on aging patients across the 8 major markets.

Sarcopenia Market Overview

Sarcopenia is characterized by a progressive decline in muscle strength and mass. Muscle weakness is a common symptom of this age-related condition. A sedentary lifestyle and unhealthy eating habits can put an individual at a higher risk of the disease. The prevalence of sarcopenia is estimated to be 10-16% among the geriatric population. The condition was reported to affect 18% of diabetic patients and 66% of patients with unresectable esophageal cancer. The increasing geriatric population base, prone to developed this skeletal muscle disorder is expected to fuel the demand for effective treatment driving sarcopenia market growth in the forecast period.

In July 2023 , a biotechnology company headquartered in France, Biophytis BSA, filed for the United States Food and Drug Administration (FDA) approval for SARA-31, the first Phase III study targeting sarcopenia. SARA-31 will evaluate Sarconeos' (BIO101) effectiveness and safety in treating sarcopenic patients prone to mobility issues. Sarconeos (an orally administered small molecule) has shown promise in Phase IIb trials. The Phase III study aims to enrol around 900 patients aged over 65 with severe sarcopenia, low walking speed, and grip strength. The development of such innovative treatment approaches to address the growing cases of sarcopenia is projected to propel the sarcopenia market demand.

The market is witnessing steady growth which can be attributed to factors such as the growing investment in research and development projects and increasing demand for pharmacological interventions aimed at enhancing muscle mass and function.

Sarcopenia Market Trends

• Increased Recognition and Diagnosis: Sarcopenia is increasingly recognized as a distinct condition. This has led to improved diagnostic criteria and screening tools to identify and manage it early.
• Nutritional Interventions: There is an increased focus on nutritional strategies, particularly protein supplementation and vitamin D, to treat or manage sarcopenia. Such interventions reflect the critical role of diet in muscle health.
• Physical Activity and Exercise Programs using Wearable Technologies: With increasing application of latest technologies such as wearable and biosensors, the sarcopenia market share is likely to augment in the forecast period. The development of wearable technology and mobile applications to monitor the physical activity of sarcopenia patients can help improve patient outcomes.
• Pharmacological Developments: Ongoing research into pharmacological treatments, such as anabolic agents and selective androgen receptor modulators (SARMs), aimed at directly enhancing muscle mass and function, are expected to influence the market landscape.

Sarcopenia Market Segmentation

Market Breakup by Treatment Type

• Protein Supplement
• Vitamin B12 Supplement
• Vitamin D & Calcium Supplement
• Pharmacotherapy
• Others

The market segmentation by treatment type includes protein supplements, vitamin B12 supplements, vitamin D & calcium supplements, pharmacotherapy, and others. Protein supplements help promote muscle protein synthesis and counteract muscle loss in sarcopenia patients. Vitamin B12 supplements help address deficiencies often observed in older adults. Vitamin D & calcium supplements address potential deficiencies associated with sarcopenia by supporting bone health and muscle function. Pharmacotherapy involves medications targeting muscle mass and function to treat sarcopenia.

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Based on the route of administration, the sarcopenia market share includes oral, parenteral, and others. In oral administration, medications are taken via mouth. On the other hand, parenteral administration involves injections or infusions.

Market Breakup by End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Major end users of the market include hospitals, homecare, specialty clinics, and others. They offer specialized expertise and care for sarcopenia patients.

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online pharmacy
• Others

The distribution channels in the sarcopenia market constitute hospital pharmacies, retail pharmacies, online pharmacies, and others. To ensure accessibility and availability of sarcopenia treatments, this segment offers various channels to cater to the diverse needs of the patients.

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• China

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China. North America dominates the regional market, attributed to the presence of key market players and a robust healthcare system. Rapid technological advancements and the growth of the elderly population in the region further bolster the market growth.

Sarcopenia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Amgen Inc.
• F-Hoffmann La-Roche
• American Way (Amway) Corporation
• Abbott laboratories, Inc.
• AbbVie Inc.
• Merck Sharp & Dohme Corp.
• AstaReal AB
• Pfizer Inc.
• Sanofi S.A.
• Nestle Health Science
• Zydus Cadila
• Bayer AG
• Amgen Inc.
• Johnson & Johnson
• Novartis AG

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Queries Solved in the Sarcopenia Market Report

• How has the sarcopenia market performed so far and how will it perform in the coming years?
• What are the major market trends influencing the market?
• What are the market's major drivers, opportunities, and restraints?
• What will be the effect of each driver, challenge, and opportunity on the market?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience rapid growth during the forecast period?
• What is incidence and prevalence of the condition?
• How does the prevalence and incidence of sarcopenia affect the market landscape?
• How does the rise in geriatric population impact the sarcopenia market size?
• What treatment type of sarcopenia will dominate the market share?
• What are the prominent diagnostic methods and tools used in the detection and monitoring of sarcopenia?
• How will the ongoing clinical trials impact the market value during the forecast period?
• What are the factors driving regional disparities in sarcopenia treatment and outcomes?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?

FAQs

• What is the sarcopenia market forecast outlook for 2024-2032?

The market is anticipated to grow at a CAGR of 4.3% during the forecast period of 2024-2032, driven by the growing geriatric population across the 8 major markets.

• What are the major factors aiding the sarcopenia market demand?

Factors such as rising healthcare expenditure, heightened patient awareness along with research activities to mitigate the impact of sarcopenia on aging patients are fuelling the demand for the market.

• What are the major sarcopenia market trends?

One of the significant trends in the market is the development of innovative and effective treatment approaches to address the growing cases of sarcopenia. In July 2023, Biophytis BSA filed for the United States Food and Drug Administration (FDA) approval for SARA-31, the first Phase III study targeting sarcopenia. SARA-31 will evaluate its product Sarconeos' (BIO101) effectiveness and safety in treating sarcopenic patients prone to mobility issues.

• What is the market segmentation based on the treatment type?

The market segmentation by treatment type includes protein supplements, vitamin B12 supplements, vitamin D & calcium supplements, pharmacotherapy, and others.

• What is the market segmentation based on the route of administration?

Based on the route of administration, the market includes oral, parenteral, and others.

• What are the major end users in market?

Major end users of the market include hospitals, homecare, specialty clinics, and others.

• What are the distribution channels of the sarcopenia market?

The distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and others.

• What are the major regional markets for sarcopenia, according to the EMR report?

The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China.

• Who are the key players involved in the sarcopenia market?

Key players involved in the market are Amgen Inc., F-Hoffmann La-Roche, American Way (Amway) Corporation, Abbott Laboratories, Inc., AbbVie Inc., Merck Sharp & Dohme Corp., AstaReal AB, Pfizer Inc., Sanofi S.A., Nestle Health Science, Zydus Cadila, Bayer AG, Amgen Inc., Johnson & Johnson., and Novartis AG.

Meta description

The sarcopenia market size is anticipated to grow at a CAGR of 4.3% during the forecast period of 2024-2032.